Biotech Stocks At 52-Week Highs - ADVB Surges +73%, BLFS Rises After Acquisition, FBRX, SLN, LBRXrttnews·1 day ago, 03:38 AMSLN-3.76%FBRX-8.24%
Silence Therapeutics (NASDAQ:SLN) Sets New 52-Week High - Here's WhyMarket Beat·Jul 17 at 11:40 AMSLN-3.76%
Silence Therapeutics 10% owner Richard Ian Griffiths disposes of ADS-linked common shares worth $16.34 millionPUBT·Jul 7 at 08:10 AMSLN-3.76%
Top Biotech Gainers: PLSM Inks Virtual Maternity Care Deal, ICCM Turns Heads, SLN Hits New Highrttnews·Jun 24 at 10:52 PMPLSM-6.28%NVCT-4.17%
This $300 Million Biotech May Be Deeply Mispriced: Analystbenzinga_article·Jun 24 at 01:22 PMSLN-3.76%
Silence Therapeutics: Divesiran and a robust siRNA pipeline target major unmet needs in PV, dyslipidemia, and obesityQuartr·Jun 23 at 03:54 PMSLN-3.76%
Silence Therapeutics updates corporate presentation highlighting Divesiran Phase 2 topline timing and pipeline progressTradingView·Jun 23 at 03:43 PMSLN-3.76%
Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Databenzinga_article·Jun 12 at 09:47 AMSLN-3.76%
Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera | SLN Stock NewsStockTitan·Jun 10 at 10:30 PMSLN-3.76%
Silence Therapeutics (NASDAQ:SLN) Posts Quarterly Earnings Results, Misses Expectations By $0.14 EPSMarket Beat·May 9 at 12:38 PMSLN-3.76%BIB-1.17%
Gyre Therapeutics shares are trading lower after the company reported worse-than-expected Q1 sales results.benzinga_article·May 7 at 11:23 AMGYRE-1.16%
